UroGen Pharma Ltd. (URGN) posted a fourth quarter net loss of $37.5 million compared to a loss of $26.0 million, a year ago. Net loss per ordinary share was $0.80 compared to a loss of $0.72. Analysts on average expected the company to report a loss per share of $0.72, for the quarter. Analysts' estimates typically exclude special items.
Revenue increased to $24.57 million from $23.53 million, last year. Underlying demand revenue increased 15% year-over-year.
The company expects full-year 2025 net product revenues from JELMYTO to be in the range of $94 to $98 million. This implies a year-over-year growth rate of approximately 8% to 12%.
Shares of UroGen Pharma are down 4% in pre-market trade on Monday.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.